AccessMyLibrary provides FREE access to over 30 million articles from top publications available through your library.
Create a link to this page
Copy and paste this link tag into your Web page or blog:
Losartan was associated with marked reductions in stroke and new-onset diabetes, compared with atenolol, in a landmark clinical trial of patients with hypertension.
"I think these results have immediate applicability to clinical practice. The message is that it matters how you lower blood pressure. We now have a treatment with benefit beyond blood pressure lowering," Dr. Bjorn Dahlof said at the annual meeting of the American College of Cardiology.
A total of 9,197 American, Scandinavian, and British patients with essential hypertension and left ventricular hypertrophy, all older than age 55, were randomized to either 50-100 mg/day of the angiotensin receptor blocker (ARB) losartan or the [beta]-blocker atenolol, with hydrochlorothiazide added as needed to reach blood pressure goals.
Achieved blood pressures were virtually identical in the two groups.
...Source: HighBeam Research, Losartan trumps atenolol. (Primary Care: Cardiology).